Trading
Nicolab
Connecting Human & Artificial Intelligence to Revolutionise Emergency Care
INDUSTRY
Medical
STATUS
Trading
OPEN TO
Public
If you are seeking to buy or sell a substantial number of shares beyond what is listed on the PrimaryMarkets Platform, please reach out to our trading team.
Investment Highlights
Company Overview
Ground-Breaking Technology
Global Solution
Connecting Human & Artificial Intelligence
Set to revolutionise Emergency Care
Focus on commercial roll-out in target markets
Key focus on Australia, US, and the Netherlands
NICO.LAB have launched StrokeViewer®, the world’s first stroke technology certified for diagnostic use.
StrokeViewer consists of a comprehensive set of tools to support the entire stroke workflow that saves critical time in stroke care, connects teams and identifies more anomalies for closer inspection.
Built by leading University medical researchers
NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Centre in the Netherlands and has offices in Australia, Europe and the United States.
An international team of researchers, developers and physicians connects human & artificial intelligence to empower physicians in emergency care with end-to-end solutions.
Local availability of StrokeViewer functionality is subject to applicable CE marking, TGA and FDA approval
Previous Funding
September 30, 2022 – Philips makes a strategic investment of A$6.45M at a price of A$1.00
June 30, 2021 – Nicolab raises A$13M in pre-IPO investment round.
Key Investors
Philips has invested A$6.45M in Nicolab as a strategic partner including a shared product roadmap for a new combined offering
Philips is market leader in Image Guided Therapy, offering Nicolab a unique position to capitalise on its strength in the market
News
Ask us a Question
Send us a message and we'll connect soon
Become a member
Become a member and elevate your experience with us!
Already have an account? Login